SCHEDULE 14A
                                 (Rule 14a-101)
                     INFORMATION REQUIRED IN PROXY STATEMENT
                            SCHEDULE 14A INFORMATION
                    Proxy Statement Pursuant to Section 14(a)
                     of the Securities Exchange Act of 1934


Filed by the Registrant [ X ]
Filed by a Party other than the Registrant [ ]
Check the appropriate box:
[ ] Preliminary Proxy Statement
[ ] Confidential, for Use of the Commission Only (as Permitted by Rule
14a-6(e)(2))
[ ] Definitive Proxy Statement
[X] Definitive Additional Materials
[ ] Solicitation Material Pursuant to Rule 14a-11(c) or rule 14a-12

                           Hemispherx Biopharma, Inc.
                (Name of Registrant as Specified in its Charter)

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

[x] No fee required.

[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

        1) Title of each class of securities to which transaction applies:

        2) Aggregate number of securities to which transaction applies:

        3) Per unit price or other underlying value of transaction computed
           pursuant to Exchange Act Rule 0-11:

        4) Proposed maximum aggregate value of transaction:

        5) Total fee paid:


[ ] Fee paid previously with preliminary materials.

[ ] Check box if any part of the fee is offset as provided by Exchange
Act Rule 0-11(a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.

        (1) Amount Previously Paid:

        (2) Form, Schedule or Registration Statement No.:

        (3) Filing Party:

        (4) Date Filed:





Company/Investor Contact:
Dianne Will
Hemispherx Biopharma, Inc.
518-398-6222
ir@hemispherx.net

 Hemispherx Biopharma Announces Cancellation of Adjourned Stockholders' Meeting

PHILADELPHIA,  PA--September  2,  2009--Hemispherx  Biopharma  (NYSE AMEX:  HEB)
announced  today that  insufficient  votes were obtained for passage of proposal
no. 3 contained in the proxy for the 2009 Annual Meeting of  Stockholders.  With
this  proposal  being the sole purpose of the  adjourned  Stockholders'  Meeting
scheduled  for  September,  4,  2009,  there is no need to hold the  meeting  on
September 4th.

As previously  announced,  the 2009 Annual Meeting of  Stockholders  was held as
scheduled  on June 24, 2009 at which  three of the four  proposals  passed.  The
Company left the polls open with regard to voting on proposal 3, an amendment of
its Certificate of Incorporation to increase the number of authorized  shares of
Common Stock from  200,000,000 to 350,000,000,  and adjourned the meeting solely
with regard to this proposal.  The Company did this due to the low vote turn out
and the requirement  that this proposal be approved by the holders of a majority
of the outstanding shares. Less than the requisite number of shares for approval
of the proposal were present at the original meeting.

The Company  believes that the low turnout of Stockholders as of the May 8, 2009
Record  Date was due to the fact that more  than 40% of its  outstanding  shares
were held  outside  the  United  States  with many of these  shares  are held at
European banks that do not  necessarily  participate in the voting of proxies of
American companies.

About Hemispherx Biopharma
Hemispherx  Biopharma,  Inc.  is a  specialty  pharma  company  engaged  in  the
manufacture  and clinical  development  of new drug  entities  for  treatment of
seriously debilitating disorders. Hemispherx's flagship products include Alferon
N Injection(R)  (FDA approved for a category of sexually  transmitted  diseases)
and the  experimental  therapeutics,  Ampligen(R)  and Oragens.  Ampligen(R) and
Oragens  represent  experimental  RNA nucleic acids being developed for globally
important debilitating diseases and disorders of the immune system. Hemispherx's
platform  technology  includes  large and small agent  components  for potential
treatment  of  various  severely  debilitating  and life  threatening  diseases.
Hemispherx has in excess of 50 issued patents  comprising its core  intellectual
property estate and a fully commercialized product (Alferon N Injection(R)). The
Company  wholly  owns and  exclusively  operates a GMP  certified  manufacturing
facility in the United  States for  commercial  products.  For more  information
please visit www.hemispherx.net.

Information  contained in this news release other than  historical  information,
should be considered  forward-looking and is subject to various risk factors and
uncertainties. For instance, the strategies and operations of Hemispherx involve
risk of competition,  changing market conditions, change in laws and regulations
affecting these industries and numerous other factors  discussed in this release
and in the Company's  filings with the Securities and Exchange  Commission.  Any
specifically referenced investigational drugs and associated technologies of the
Company  (including  Ampligen(R),  Alferon LDO and Oragens) are  experimental in
nature  and as such  are not  designated  safe  and  effective  by a  regulatory
authority for general use and are legally available only through clinical trials
with the referenced  disorders.  The  forward-looking  statements  represent the
Company's  judgment  as of the  date of this  release.  The  Company  disclaims,
however,  any intent or obligation to update these  forward-looking  statements.
Clinical trials for other potential indications of the approved biologic Alferon
N Injection(R) do not imply that the product will ever be specifically  approved
commercially for these other treatment indications; similarly, the completion of
the NDA filing  process  with  Ampligen(R)  does not imply that the product will
ever be approved commercially.